1586 - Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy and Safety Outcomes Through Week 96 by Race

Friday, October 21, 2022

4:15 PM – 4:30 PM US ET

Location: 206

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Co-Author(s)

Parul Patel, MSW

Director, Clinical Pharmacology
ViiV Healthcare
Durham, North Carolina, United States

Disclosure: Disclosure(s): GlaxoSmithKline: Stocks/Bonds (); ViiV Healthcare Ltd: Employee ()
EE

Emilie Elliot, MD

ViiV Healthcare
Tres Cantos, Madrid, Spain

Disclosure: Disclosure(s): ViiV Healthcare Ltd: Employee ()
RD

Ronald D’Amico, D.O., MSc

ViiV Healthcare
Durham, North Carolina, United States

Disclosure: Disclosure(s): GlaxoSmithKline: Stocks/Bonds (); ViiV Healthcare Ltd: Employee ()
LG

Louise Garside, PhD

PHASTAR
Macclesfield, England, United Kingdom

Disclosure: Disclosure(s): GlaxoSmithKline: Stocks/Bonds ()
CS

Conor Smith, BSc

Parexel International
Sheffield, England, United Kingdom

Disclosure: Disclosure(s): No financial relationships to disclose
JR

Jeremy Roberts, MSc

Manager, Statistics
GlaxoSmithKline
Mississauga, Ontario, Canada

Disclosure: Disclosure(s): GlaxoSmithKline: Employee (), Stocks/Bonds ()
JP

Joseph W. Polli, PhD

ViiV Healthcare
Durham, North Carolina, United States

Disclosure: Disclosure(s): GlaxoSmithKline: Stocks/Bonds (); ViiV Healthcare Ltd: Employee ()

Presenting Author(s)

Moti Ramgopal, MD, FACP, FIDSA

Medical Director
Midway Immunology and Research Center
Fort Pierce, FL, United States

Disclosure: Disclosure(s): AbbVie: Grant/Research Support (); Gilead Sciences Inc.: Advisor/Consultant (), Grant/Research Support (), Honoraria (), Stocks/Bonds (); GlaxoSmithKline: Advisor/Consultant (), Grant/Research Support (), Honoraria (), Stocks/Bonds (); Janssen Research & Development LLC: Advisor/Consultant (), Grant/Research Support (), Honoraria (), Stocks/Bonds (); Merck: Advisor/Consultant (), Grant/Research Support (), Honoraria (), Stocks/Bonds (); Shionogi: Grant/Research Support (); ViiV: Advisor/Consultant (), Grant/Research Support ()

Slides

Co-Author(s)

Princy N. Kumar, MD

Professor, Medicine; Chief, Division of Infectious Diseases and Travel Medicine
Georgetown University Medical Center, Washington, DC, USA
Washington, District of Columbia, United States

Disclosure: Disclosure(s): American Gene Technologies: Grant/Research Support (); BioHaven: Grant/Research Support (); Eli Lilly: Grant/Research Support (); Gilead: Advisor/Consultant (), Grant/Research Support (), Stocks/Bonds (); GSK: Grant/Research Support (), Stocks/Bonds (); Johnson&Johnson: Advisor/Consultant (), Stocks/Bonds (); Merck: Advisor/Consultant (), Grant/Research Support (), Stocks/Bonds (); Moderna: Stocks/Bonds (); Pfizer: Stocks/Bonds (); Regeneron: Grant/Research Support (); TheraTechnologies: Advisor/Consultant (); ViiV: Advisor/Consultant ()
Olayemi Osiyemi, MD

President
Triple O Research Institute
West Palm Beach, Florida, United States

Disclosure: Disclosure(s): Gilead: Advisor/Consultant (); gsk: Advisor/Consultant (); viiv: Advisor/Consultant ()
BB

Bryan Baugh, MD

Global Affairs Leader, Infectious Diseases and Vaccines
Janssen Research & Development LLC
Raritan, New Jersey, United States

Disclosure: Disclosure(s): Janssen Research & Development LLC: Employee (), Stocks/Bonds ()
Jv

Jean A. van Wyk, MB,ChB; MFPM

Global Medical Lead, VP
ViiV Healthcare Limited
Brentford, England, United Kingdom

Disclosure: Disclosure(s): ViiV Healthcare Limited: I am an employee of ViiV Healthcare (), Stocks/Bonds ()

Disclosure(s):

Parul Patel, MSW: GlaxoSmithKline: Stocks/Bonds (); ViiV Healthcare Ltd: Employee ()

Emilie Elliot, MD: ViiV Healthcare Ltd: Employee ()

Ronald D’Amico, D.O., MSc: GlaxoSmithKline: Stocks/Bonds (); ViiV Healthcare Ltd: Employee ()

Louise Garside, PhD: GlaxoSmithKline: Stocks/Bonds ()

Conor Smith, BSc: No financial relationships to disclose

Jeremy Roberts, MSc: GlaxoSmithKline: Employee (), Stocks/Bonds ()

Joseph W. Polli, PhD: GlaxoSmithKline: Stocks/Bonds (); ViiV Healthcare Ltd: Employee ()

Moti Ramgopal, MD, FACP, FIDSA: AbbVie: Grant/Research Support (); Gilead Sciences Inc.: Advisor/Consultant (), Grant/Research Support (), Honoraria (), Stocks/Bonds (); GlaxoSmithKline: Advisor/Consultant (), Grant/Research Support (), Honoraria (), Stocks/Bonds (); Janssen Research & Development LLC: Advisor/Consultant (), Grant/Research Support (), Honoraria (), Stocks/Bonds (); Merck: Advisor/Consultant (), Grant/Research Support (), Honoraria (), Stocks/Bonds (); Shionogi: Grant/Research Support (); ViiV: Advisor/Consultant (), Grant/Research Support ()

Princy N. Kumar, MD: American Gene Technologies: Grant/Research Support (); BioHaven: Grant/Research Support (); Eli Lilly: Grant/Research Support (); Gilead: Advisor/Consultant (), Grant/Research Support (), Stocks/Bonds (); GSK: Grant/Research Support (), Stocks/Bonds (); Johnson&Johnson: Advisor/Consultant (), Stocks/Bonds (); Merck: Advisor/Consultant (), Grant/Research Support (), Stocks/Bonds (); Moderna: Stocks/Bonds (); Pfizer: Stocks/Bonds (); Regeneron: Grant/Research Support (); TheraTechnologies: Advisor/Consultant (); ViiV: Advisor/Consultant ()

Olayemi Osiyemi, MD: Gilead: Advisor/Consultant (); gsk: Advisor/Consultant (); viiv: Advisor/Consultant ()

Bryan Baugh, MD: Janssen Research & Development LLC: Employee (), Stocks/Bonds ()

Jean A. van Wyk, MB,ChB; MFPM: ViiV Healthcare Limited: I am an employee of ViiV Healthcare (), Stocks/Bonds ()